A Phase 3 interventional study of K-877 and Placebo in Type2 Diabetes and Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Terminated at 888 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Dyslipidemias by Kowa Company, Ltd. — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Kowa Company, Ltd..
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one has the largest enrollment, is the only one that started in 2017, is one of 14 in phase 3, and was the 16th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 20 studies in Dyslipidemias by Kowa Company, Ltd. is open now. The open studies under Dyslipidemias, anywhere →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10,544 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 290 across the 20 interventional studies. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of:
A multi-regional clinical trial with participating sites in the following countries. India is being conducted under a previous protocol version due to regulatory requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 diabetes of longer than 12 weeks duration documented in medical records, for example: local laboratory evidence through medical record review of elevated (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour ≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance testing, or random value ≥ 200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either
Age ≥ 18 years and established systemic atherosclerosis (secondary prevention cohort), defined as any 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
K-877 (pemafibrate) tablet twice daily.
Drug: K-877
Matching K-877 placebo tablet twice daily.
Drug: Placebo
0.2mg tablet
Also known as: pemafibrate
K-877 matching placebo tablet
Number of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death)
Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint, which includes nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, or cardiovascular (CV) death. Each participant is counted only once, regardless of any subsequent events.
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death)
The 4-component composite secondary endpoints events are nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or cardiovascular death
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death)
Number of Participants with First Occurrence of Composite Cardiovascular Events (nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death)
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure
Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or hospitalization for heart failure
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality
Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or all-cause mortality.
Time frame: From Baseline to a Median of 3.3 Years
Total Number of Events of the 4-component Composite Primary Endpoint
Total number of events for the 4-component composite primary endpoint, counting all occurrences, including multiple events in the same participant. The endpoint events include nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, and cardiovascular (CV) death.
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD)
Any new or worsening Peripheral artery disease (PAD), defined as incidence of lower extremity revascularization, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing (eg, toe-brachial index, angiogram, or other imaging study)
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Nonfatal Myocardial Infarction
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Nonfatal Ischemic Stroke
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Coronary Revascularization
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of Cardiovascular Death
Time frame: From Baseline to a Median of 3.3 Years
Number of Participants With First Occurrence of the 4-component Composite Endpoint by PPAR-α Gene Variant Subgroup (TT, CT, CC)
Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death), reported as a subgroup analysis by PPAR-α gene variants (TT, CT, CC).
Time frame: From Baseline to a Median of 3.3 Years
Percent Change From Baseline to Month 4 for Total Cholesterol (TC)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Fasting Triglycerides
Time frame: Baseline to 4 Months
Percent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Calculated VLDL Cholesterol
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 4 for Apolipoprotein E (ApoE)
Time frame: Baseline to Month 4
Percent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol
Time frame: Baseline to Month 6
| Milestone | Pemafibrate | Placebo |
|---|---|---|
| Started | 5269 | 5275 |
| Completed | 4647 | 4674 |
| Not completed | 622 | 601 |
Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint, which includes nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, or cardiovascular (CV) death. Each participant is counted only once, regardless of any subsequent events.
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death) | 590 | 570 |
The 4-component composite secondary endpoints events are nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or cardiovascular death
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death) | 447 | 427 |
Number of Participants with First Occurrence of Composite Cardiovascular Events (nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death)
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death) | 396 | 386 |
Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or hospitalization for heart failure
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure | 670 | 645 |
Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or all-cause mortality.
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality | 830 | 806 |
Total number of events for the 4-component composite primary endpoint, counting all occurrences, including multiple events in the same participant. The endpoint events include nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, and cardiovascular (CV) death.
| Events | Pemafibrate | Placebo |
|---|---|---|
| Total Number of Events of the 4-component Composite Primary Endpoint | 895 | 892 |
Any new or worsening Peripheral artery disease (PAD), defined as incidence of lower extremity revascularization, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing (eg, toe-brachial index, angiogram, or other imaging study)
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD) | 138 | 159 |
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Nonfatal Myocardial Infarction | 210 | 182 |
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Nonfatal Ischemic Stroke | 96 | 106 |
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Coronary Revascularization | 340 | 347 |
| participants | Pemafibrate | Placebo |
|---|---|---|
| Number of Participants With First Occurrence of Cardiovascular Death | 145 | 139 |
Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death), reported as a subgroup analysis by PPAR-α gene variants (TT, CT, CC).
| Count of Participants | Pemafibrate | Placebo |
|---|---|---|
| TT variant | 114 | 117 |
| CT variant | 177 | 156 |
| CC variant | 63 | 65 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Total Cholesterol (TC) | 5.235 ± 23.7683 | 4.562 ± 23.9991 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Fasting Triglycerides | -23.860 ± 49.2289 | 2.593 ± 60.6399 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C) | 10.856 ± 24.7407 | 6.004 ± 21.7838 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C) | 5.219 ± 31.9262 | 5.502 ± 31.9739 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Calculated VLDL Cholesterol | -22.788 ± 32.5741 | -1.601 ± 36.4352 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1) | 4.878 ± 19.3749 | 3.956 ± 18.5293 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3) | -23.397 ± 31.5756 | 4.861 ± 56.0921 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 4 for Apolipoprotein E (ApoE) | -6.5201 ± 30.89475 | -0.5209 ± 31.79989 |
| Percent Change | Pemafibrate | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol | -21.27 ± 46.506 | 10.60 ± 54.029 |
Collected over From Baseline to a Median of 3.3 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemafibrate | 308/5,264 (5.9%) | 1,715/5,264 (32.6%) | 2,817/5,264 (53.5%) |
| Placebo | 310/5,274 (5.9%) | 1,663/5,274 (31.5%) | 2,883/5,274 (54.7%) |
| Event | Pemafibrate | Placebo |
|---|---|---|
| Angina unstableCardiac disorders | 97/5264 | 95/5274 |
| Acute myocardial infarctionCardiac disorders | 97/5264 | 93/5274 |
| COVID-19 pneumoniaInfections and infestations | 95/5264 | 91/5274 |
| PneumoniaInfections and infestations | 82/5264 | 87/5274 |
| Cardiac failureCardiac disorders | 84/5264 | 68/5274 |
| Atrial fibrillationCardiac disorders | 53/5264 | 73/5274 |
| Angina pectorisCardiac disorders | 69/5264 | 59/5274 |
| Coronary artery diseaseCardiac disorders | 66/5264 | 59/5274 |
| Acute kidney injuryRenal and urinary disorders | 66/5264 | 42/5274 |
| Peripheral arterial occlusive diseaseVascular disorders | 37/5264 | 60/5274 |
| Event | Pemafibrate | Placebo |
|---|---|---|
| Diabetes mellitusMetabolism and nutrition disorders | 738/5264 | 677/5274 |
| HypertensionVascular disorders | 683/5264 | 664/5274 |
| Urinary tract infectionInfections and infestations | 417/5264 | 461/5274 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 417/5264 | 454/5274 |
| COVID-19Infections and infestations | 361/5264 | 377/5274 |
| NasopharyngitisInfections and infestations | 358/5264 | 354/5274 |
| Diabetic nephropathyRenal and urinary disorders | 358/5264 | 343/5274 |
| Back painMusculoskeletal and connective tissue disorders | 311/5264 | 355/5274 |
| DiarrhoeaGastrointestinal disorders | 308/5264 | 343/5274 |
| InfluenzaInfections and infestations | 251/5264 | 290/5274 |
The Intent to treat (ITT) population included all randomized subjects who received at least 1 dose of study treatment without GCP deviations.
| Age, Continuous(Years) | Pemafibrate | Placebo | Total |
|---|---|---|---|
| Mean | 63.28 ± 8.524 | 63.56 ± 8.411 | 63.42 ± 8.468 |
| Sex: Female, Male(Participants) | Pemafibrate | Placebo | Total |
|---|---|---|---|
| Female | 1443 | 1448 | 2891 |
| Male | 3797 | 3809 | 7606 |
| Ethnicity (NIH/OMB)(Participants) | Pemafibrate | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1014 | 1007 | 2021 |
| Not Hispanic or Latino | 4187 | 4213 | 8400 |
| Unknown or Not Reported | 39 | 37 | 76 |
| Race/Ethnicity, Customized(Participants) | Pemafibrate | Placebo | Total |
|---|---|---|---|
| White | 4484 | 4549 | 9033 |
| Black or African American | 134 | 136 | 270 |
| American Indian or Alaska Native | 73 | 76 | 149 |
| Asian Indian | 97 | 80 | 177 |
| Bangladeshi | 0 | 3 | 3 |
| Chinese | 3 | 1 | 4 |
| Filipino | 2 | 5 | 7 |
| Japanese | 162 | 146 | 308 |
| Korean | 0 | 0 | 0 |
| Pakistani | 13 | 6 | 19 |
| Vietnamese | 1 | 0 | 1 |
| Other Asian | 13 | 10 | 23 |
| Native Hawaiian | 0 | 0 | 0 |
| Guamanian or Chamorro | 0 | 0 | 0 |
| Samoan | 0 | 0 | 0 |
| Other Pacific Islander | 1 | 0 | 1 |
| Multiracial | 29 | 32 | 61 |
| Other | 208 | 201 | 409 |
| Declined | 20 | 12 | 32 |
| Cardiovascular Diseases and Risk Factors at Baseline(Participants) | Pemafibrate | Placebo | Total |
|---|---|---|---|
| Statin Status — No | 220 | 219 | 439 |
| Statin Status — Yes | 5020 | 5038 | 10058 |
| Established CV Disease — No | 1695 | 1713 | 3408 |
| Established CV Disease — Yes | 3545 | 3544 | 7089 |
Showing the first 100 of 888 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Jul 2022, 64 months.
Results were first posted in Sep 2025, 3 years 1 month after primary completion. A results delay was requested in Jul 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemafibrate
Kowa Research Institute, Inc. →